Loading...
Relapsed and refractory (R/R) aggressive B-cell lymphomas may respond to immunotherapeutic and targeted agents, but remissions are often incomplete and short-lived. Now, researchers investigated whether targeting multiple pathways with a combination of medications might improve remission rates.
In this single-center, phase 1b/2 trial, patients with R/R diffuse large B-cell lymphoma (DLBCL) received the oral agents venetoclax (a B-cell lymphoma 2 inhibitor), ibrutinib (a Bruton tyrosine kinase inhibitor), prednisone, and lenalidomide (an immunomodulatory agent) plus the anti-CD20 monoclonal antibody obinutuzumab. The regimen, referred to as ViPOR, was administered every 21 days for six cycles, with the oral drugs administered on days 1 throug…